Proton Therapy for Prostate Cancer: Key Takeaways

Proton Therapy for Prostate Cancer: Key Takeaways

Proton Therapy vs. IMRT for Prostate Cancer: What the Evidence, the Guidelines, and the Courts Say Now

Informed Prostate Cancer Support Group (IPCSG) Newsletter — Patient Education Series — July 2026

BLUF (Bottom Line Up Front): 

For most men with newly diagnosed low- or intermediate-risk localized prostate cancer, the best available randomized evidence — the phase III PARTIQoL trial — shows that proton beam therapy (PBT) and intensity-modulated radiation therapy (IMRT) produce statistically indistinguishable outcomes: roughly 93–94% five-year progression-free survival with both, and no meaningful difference in bowel, urinary, sexual, or hormonal side effects. Proton therapy typically costs substantially more, and insurers have been repeatedly sued — and have paid multimillion-dollar settlements — over improper denials, even though the treatments perform similarly for the average patient. The more promising, still-emerging uses for protons are in higher-risk/nodal disease and in re-treating men who received prior pelvic radiation, where minimizing dose to already-irradiated tissue matters more. Bottom line for shared decision-making: choose based on facility experience, access, and out-of-pocket cost — not on the assumption that "newer" or "more expensive" means "better."

1. The Central Randomized Evidence: PARTIQoL

The question of whether proton therapy's theoretical physical advantages — a sharper radiation dose fall-off beyond the tumor target — translate into measurably better outcomes for localized prostate cancer was tested directly in the NCI-funded, multi-center PARTIQoL trial (Prostate Advanced Radiation Technologies Investigating Quality of Life; ClinicalTrials.gov NCT01617161). Between 2012 and 2021, PARTIQoL randomized 450 men with low- or intermediate-risk localized prostate cancer to receive either PBT or IMRT, without hormone therapy, and followed them for patient-reported bowel, urinary, and sexual function for five years using the validated EPIC questionnaire, with the primary endpoint being bowel function at 24 months.^[1,2,3]

Lead investigator Jason Efstathiou, MD, DPhil, of Massachusetts General Hospital, presented the final results as a late-breaking abstract at the American Society for Radiation Oncology (ASTRO) 2024 Annual Meeting, with the full peer-reviewed manuscript subsequently published in the International Journal of Radiation Oncology, Biology, Physics (Red Journal).^[1,4] The findings, in brief:

Outcome	Proton Therapy (PBT)	IMRT
5-year progression-free survival	93.4%	93.7%
Bowel function (EPIC, 24 mo, primary endpoint)	No significant difference	No significant difference
Urinary function	No significant difference	No significant difference
Sexual function	No significant difference	No significant difference
Hormonal/other quality-of-life domains	No significant difference	No significant difference

Investigators reported that this held true across every pre-specified subgroup, including age, use of a rectal spacer, and whether a moderately hypofractionated (shorter) course was used.^[2] At an ASTRO press briefing, incoming ASTRO president Sameer Keole, MD, of Mayo Clinic Arizona, characterized the trial as a modern-era comparison showing excellent, essentially equal cancer control and toxicity for both particle and photon-based radiation.^[5] The takeaway echoed by multiple independent outlets covering the trial (UroToday, Renal & Urology News, Oncology News Central, Cancer Nursing Today, the ASCO Post) was consistent: contemporary IMRT and PBT are both excellent options, and neither demonstrated superiority over the other for this patient population.^[2,3,5,6,7]

What this means in the exam room: If you have low- or intermediate-risk localized disease, you should expect your radiation oncologist to describe proton therapy and IMRT as equally effective, equally safe options in 2026 — not to steer you toward proton therapy on the assumption that its dosimetric elegance automatically produces a better outcome for you personally.

2. Where Protons May Still Have a Real Edge

PARTIQoL answered the question for the most common patient population — low- and intermediate-risk, primary treatment. It did not settle the question for two other groups where active research continues:

Higher-risk and nodal disease

Because larger treatment volumes (including pelvic lymph nodes) expose more healthy tissue to radiation, some radiation oncologists hypothesize that proton therapy's steeper dose fall-off could matter more in this setting. A randomized phase II trial presented at ASTRO 2025 directly compared hypofractionated proton therapy and IMRT for recurrent, node-positive prostate cancer requiring pelvic and/or para-aortic nodal irradiation. The trial enrolled 81 patients (34 to proton therapy, 47 to IMRT) and evaluated whether moderately hypofractionated nodal radiation increased genitourinary or gastrointestinal toxicity compared with conventional fractionation, with all patients also receiving 12–18 months of androgen deprivation therapy.^[8] This remains an active area of study rather than a settled answer, and the evidence base for higher-risk/nodal disease is far less mature than for localized low/intermediate-risk disease.^[8]

Re-treatment (salvage) after prior pelvic radiation

For men whose cancer recurs locally after a prior full course of radiation, re-irradiating the same tissue carries a materially higher risk of rectal and urinary complications because that tissue has already absorbed a full radiation dose. This is widely viewed as one of proton therapy's most defensible current indications, because its physical properties allow clinicians to spare previously irradiated normal tissue more effectively.^[9] A 2026 retrospective series from the New York Proton Center examined the feasibility of combining perirectal spacer placement with salvage proton therapy in 30 patients who had already undergone prior local treatment (HIFU, brachytherapy, or EBRT), finding the combined approach feasible and a reasonable strategy for minimizing rectal toxicity in this higher-risk retreatment population.^[9] Current AUA/ASTRO/SUO joint guidelines on salvage therapy after radiotherapy note that reirradiation options — including SBRT, brachytherapy, and proton therapy — are reasonable considerations for carefully selected patients with biopsy-confirmed local recurrence, though the guidelines do not endorse one radiation modality over another as universally superior.^[10]

3. The Cost and Coverage Reality

Proton therapy remains substantially more expensive to deliver than IMRT. A single-room proton treatment facility can cost roughly $50 million to build, compared with approximately $5 million for a standard IMRT linear accelerator, and Medicare reimbursement for a full course of proton therapy typically runs $10,000–$20,000 higher than photon-based IMRT, with an even larger gap in the commercial insurance market.^[11,12] Reflecting this, the National Comprehensive Cancer Network's (NCCN) 2026 prostate cancer guidelines explicitly flag the "potential financial toxicity" of proton therapy and advise that its higher cost should factor into the treatment discussion specifically because tumor control and side-effect profiles are similar between the two modalities.^[11]

Insurance coverage for proton therapy in prostate cancer has long been inconsistent. A retrospective study of 1,592 insured patients recommended for proton therapy between 2014 and 2018 found that only about 79% belonged to plans whose written policy covered proton therapy for prostate cancer at all, and that approval depended far more on insurance type than on any clinical risk factor.^[13] Medicare generally covers proton therapy for prostate cancer when documented as medically necessary, subject to standard Part B cost-sharing, but commercial insurers have frequently classified it as "experimental," "investigational," or "not more effective than" IMRT — designations that plaintiffs' attorneys and, in several cases, courts have found to be scientifically outdated and used in bad faith.^[14,15]

4. Litigation and Settlements: The Insurance Fight Is Real and Ongoing

This is not merely a legal-marketing talking point — it shows up in actual court dockets and settlements:

• Aetna — $3.42 million ERISA class settlement (2025). Aetna agreed to resolve claims that it improperly denied precertification and post-service claims for proton beam therapy in localized prostate cancer between January 2015 and March 2024, citing grounds such as "experimental," "investigational," or "not superior to" alternative treatment. Eligible class members could claim a flat $12,000 payment, or up to $48,000 with proof of payment; the claims deadline was October 3, 2025, with final court approval addressed at a November 18, 2025 hearing.^[15]
• UnitedHealthcare — $6.75 million (member payments) / roughly $9.25 million total settlement (2025). UnitedHealthcare Insurance Co. and UnitedHealthcare Services LLC agreed to pay up to $75,000 per claimant to members whose proton beam radiation therapy claims were denied for prostate, primary central nervous system, cervical, or gynecological cancers between March 2016 and August 2023. As part of the settlement, UnitedHealthcare also agreed to revise its proton beam therapy coverage policy going forward — a structural change plaintiffs said should make future approvals easier to obtain.^[16,17]
• Historical backdrop — Florida federal litigation against UnitedHealthcare (2019). An earlier class action over UnitedHealthcare's denial of proton therapy for prostate cancer as "unproven" drew national attention when the presiding federal judge, himself a prostate cancer survivor, recused himself due to personal insight into the case, after stating on the record that it is medically well established that proton radiation is not experimental and produces less collateral tissue damage than conventional radiation. UnitedHealthcare subsequently revised its coverage policy to recognize proton therapy as clinically proven for prostate cancer.^[18]
• Ongoing exposure. Plaintiffs' firms report that thousands of cancer patients have pursued bad-faith insurance claims over proton therapy denials nationally, with at least one large jury verdict awarding roughly $200 million (combined compensatory and punitive damages) against an insurer found to have acted in bad faith in a proton therapy coverage dispute.^[19,20]

Practical note for patients: If your oncology team recommends proton therapy and your insurer denies it citing "experimental" or "not medically necessary," that denial rationale is increasingly out of step with current medical consensus and has repeatedly lost in court or triggered settlements. You are entitled to an internal appeal, and, if that fails, an external review or ERISA lawsuit. Keep every denial letter, and ask your insurer's medical director to explain the denial in writing against the current clinical evidence, including the PARTIQoL results described above.

5. Updated Clinical Guidelines (2026)

The NCCN's current prostate cancer guidelines (Version 5.2026, with related Guidelines Insights published in the Journal of the National Comprehensive Cancer Network in May 2026) continue to list external beam radiotherapy — whether delivered by photons (IMRT/3D-conformal) or protons — as an appropriate primary treatment option across risk groups, without designating proton therapy as preferred over IMRT for localized disease. Other notable 2026 guideline changes include elimination of the "very-low-risk" risk category, updated principles for active surveillance, and new caution regarding focal therapy in newly diagnosed patients — changes that are procedural/staging in nature rather than specific to the proton-versus-photon question, but relevant context for anyone reviewing their own risk stratification.^[21]

6. Bottom Line for Shared Decision-Making

1. For low- and intermediate-risk localized prostate cancer, present proton therapy and IMRT as equally effective, similarly well-tolerated options — this is now supported by Level 1 randomized evidence (PARTIQoL), not just consensus opinion.
2. Discuss real, non-hypothetical cost exposure up front, including facility fees, coinsurance, and the possibility of a coverage denial and appeal process.
3. Consider proton therapy more strongly in two specific situations that remain under active investigation: retreatment after prior pelvic radiation, and higher-risk disease requiring nodal irradiation — while recognizing the evidence there is still maturing.
4. If a denial occurs, know that "experimental" and "unproven" are increasingly difficult positions for insurers to defend, both scientifically and in litigation.
5. Choose your treatment center based on radiation oncology team experience and volume, access/logistics (proton centers are geographically limited), and your own priorities — not on the unexamined assumption that newer technology equals better outcomes.

Verified Sources

1. Efstathiou JA, Yeap BY, Michalski JM, et al. Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. Presented as Abstract LBA01, ASTRO Annual Meeting, September 30, 2024; published in the Red Journal, October 2024. https://www.redjournal.org/article/S0360-3016(24)03237-1/fulltext
2. UroToday. "ASTRO 2024: Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III Randomized Clinical Trial of Proton Therapy vs IMRT for Localized Prostate Cancer." September 30, 2024. urotoday.com
3. ASCO Post. "Proton Therapy and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer." April 25, 2025. ascopost.com
4. Wisdom AJ, et al. "Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial." Int J Radiat Oncol Biol Phys. March 2025. PubMed ID 39357788. pubmed.ncbi.nlm.nih.gov/39357788
5. Oncology News Central. "For Localized Prostate Cancer Treatment, Proton Therapy and IMRT Are Excellent Options." October 3, 2024. oncologynewscentral.com
6. Renal & Urology News. "Proton Therapy, IMRT for Prostate Cancer Offer Similar Quality of Life." October 7, 2024. renalandurologynews.com
7. Cancer Nursing Today. "PARTIQoL Trial: IMRT, Proton Therapy Offer Similar Efficacy, Quality of Life in Prostate Cancer." September 30, 2024. cancernursingtoday.com
8. Medscape. "Proton Therapy for Prostate Cancer: What Should Clinicians Do With the Latest Evidence?" July 1, 2026 (editorial synthesis of PARTIQoL and NCCN guidance).
9. UroToday. "ASTRO 2025: A Randomized, Parallel Phase II Trial of Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer with Pelvic and/or Para-aortic Lymph Node Involvement." October 1, 2025. urotoday.com
10. Yacoub I, Mehta K, Gorovets D, et al. "Feasibility and Outcomes of Perirectal Spacer Implantation in Previously Treated Prostate Cancer Patients Undergoing Salvage Proton Therapy Radiation." Adv Radiat Oncol. DOI: 10.1016/j.adro.2025.101985. Published online February 9, 2026. ncbi.nlm.nih.gov/pmc/articles/PMC12914100
11. American Urological Association / ASTRO / Society of Urologic Oncology. "Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III." J Urol. DOI: 10.1097/JU.0000000000003890. auajournals.org
12. Medscape. "The Controversy Over Proton Therapy for Prostate Cancer." April 8, 2026. medscape.com/viewarticle/controversy-over-proton-therapy-prostate-cancer-2026a1000ar6
13. Penn LDI (Leonard Davis Institute of Health Economics). "How to Pay for Proton Therapy in Cancer Clinical Trials." ldi.upenn.edu
14. PMC (National Library of Medicine). "Insurance Approval for Definitive Proton Therapy for Prostate Cancer." pmc.ncbi.nlm.nih.gov/articles/PMC8768894
15. Medicare.org. "Does Medicare Cover Proton Therapy?" Updated February 19, 2026. medicare.org
16. Top Class Actions. "$3.42M Aetna Proton Beam Therapy Class Action Lawsuit Settlement." August 15, 2025. topclassactions.com
17. ClaimDepot. "Claim Your Share of the $6.75M UnitedHealthcare Proton Therapy Denial Class Action Settlement." Updated January 8, 2026. claimdepot.com
18. Becker's Payer Issues. "UnitedHealth Settles Cancer Coverage Suit for $9M." May 12, 2025. beckerspayer.com
19. Gianelli & Morris. "Proton Beam Therapy Insurance Denied?" (Summary of 2019 Florida federal litigation against UnitedHealthcare, including judicial recusal.) gmlawyers.com
20. Law Office of Matthew L. Sharp. "At the Mercy of Your Insurance Company: Proton Therapy Denials." October 22, 2025. mattsharplaw.com
21. Morgan & Morgan (ForThePeople.com). "Why Do Insurance Companies Say 'No' to Proton Beam Therapy? What Prostate Cancer Patients Need to Know." February 24, 2026. forthepeople.com
22. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, Version 5.2026; and Spratt DE, et al. "NCCN Guidelines Insights: Prostate Cancer, Version 5.2026." J Natl Compr Canc Netw. 2026 May;24(5):140-149. DOI: 10.6004/jnccn.2026.0023. nccn.org | pubmed.ncbi.nlm.nih.gov/42134408

Disclaimer: This article is provided for patient education purposes by the Informed Prostate Cancer Support Group (IPCSG) and is not a substitute for individualized medical advice. Treatment decisions should always be made in consultation with your urologist and radiation oncologist, taking into account your specific pathology, risk group, prior treatments, insurance coverage, and personal priorities. Court settlement terms, coverage policies, and clinical guidelines change frequently; verify current details directly with the cited sources before relying on them for legal or insurance appeal purposes.